ACEi + ARB, SGLT2i, finerenone, semaglutide, pentoxifylline, hydrochlorothiazide, baricitinib

This is a **combination regimen** consisting of multiple classes of drugs commonly used in cardiovascular, renal, metabolic, and inflammatory diseases. The drugs included are: - **ACE inhibitors (ACEi):** Block the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and blood pressure. - **Angiotensin receptor blockers (ARB):** Inhibit angiotensin II receptor type 1, reducing blood pressure and aldosterone secretion. - **SGLT2 inhibitors (SGLT2i):** Lower blood glucose by inhibiting sodium-glucose co-transporter 2 in the kidney, promoting glucosuria. - **Finerenone:** A non-steroidal mineralocorticoid receptor antagonist that reduces inflammation and fibrosis. - **Semaglutide:** A glucagon-like peptide 1 receptor agonist (GLP-1 RA) that increases insulin secretion, suppresses glucagon, and slows gastric emptying. - **Pentoxifylline:** A methylxanthine derivative that improves blood flow by reducing blood viscosity and has anti-inflammatory effects[3][5]. - **Hydrochlorothiazide:** A thiazide diuretic that inhibits sodium-chloride symporter in the distal convoluted tubule, increasing urine output and lowering blood pressure[1][4][6]. - **Baricitinib:** A Janus kinase (JAK) inhibitor that modulates the activity of JAK1 and JAK2, reducing cytokine-mediated inflammation. This combination is not a marketed drug product, but a theoretical or experimental regimen involving these agents.